Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has received a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $7.13.

A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 23rd. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 9th. Jefferies Group LLC reaffirmed a “buy” rating and set a $7.00 price target (down from $8.00) on shares of Dicerna Pharmaceuticals in a research note on Sunday, April 2nd. Finally, Leerink Swann reaffirmed a “mkt perform” rating on shares of Dicerna Pharmaceuticals in a research note on Wednesday, February 1st.

TRADEMARK VIOLATION NOTICE: This news story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/05/30/dicerna-pharmaceuticals-inc-drna-receives-consensus-rating-of-buy-from-analysts.html.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by $0.03. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.08 million.

Several institutional investors have recently bought and sold shares of the company. Palo Alto Investors LLC boosted its stake in shares of Dicerna Pharmaceuticals by 204.2% in the first quarter. Palo Alto Investors LLC now owns 481,519 shares of the biopharmaceutical company’s stock worth $1,637,000 after buying an additional 323,240 shares during the last quarter. Paloma Partners Management Co boosted its stake in shares of Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 53,131 shares during the last quarter. Sabby Management LLC boosted its stake in shares of Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 100,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Dicerna Pharmaceuticals by 2.4% in the first quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock worth $1,423,000 after buying an additional 9,818 shares during the last quarter. Finally, UBS Group AG boosted its stake in shares of Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock worth $968,000 after buying an additional 1,599 shares during the last quarter. 58.56% of the stock is currently owned by institutional investors and hedge funds.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.